Boehringer Ingelheim's oral HER2-targeted drug, Hernexeos (zongertinib), received accelerated FDA approval for advanced non-small cell lung cancer (NSCLC) patients harboring HER2 tyrosine kinase domain mutations. The approval positions Hernexeos as a new treatment option for unresectable or previously treated NSCLC. Thermo Fisher Scientific concurrently secured FDA approval for its Oncomine Dx Target Test, a companion diagnostic designed to identify suitable NSCLC patients for Hernexeos therapy. These developments signify notable progress in targeted therapies and precision diagnostics for lung cancer management.